Geode Capital Management
ADCT icon

Geode Capital Management’s ADC Therapeutics ADCT Stock Holding History

Geode Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
1,445,546
+241,790
+20% +$705K ﹤0.01% 3246
2026
Q1 		$4.51M Buy
1,203,756
+207,233
+21% +$817K ﹤0.01% 2790
2025
Q4 		$3.52M Buy
996,523
+133,589
+15% +$542K ﹤0.01% 2943
2025
Q3 		$3.45M Buy
862,934
+4,138
+0.5% +$13K ﹤0.01% 2962
2025
Q2 		$2.3M Sell
858,796
-110,951
-11% -$233K ﹤0.01% 3096
2025
Q1 		$1.37M Buy
969,747
+6,638
+0.7% +$11.3K ﹤0.01% 3192
2024
Q4 		$1.92M Buy
963,109
+9,938
+1% +$26K ﹤0.01% 3143
2024
Q3 		$3M Buy
953,171
+128,454
+16% +$405K ﹤0.01% 2992
2024
Q2 		$2.61M Buy
+824,717
New +$3.28M ﹤0.01% 3042

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management's ADCT Position: Q2 2026 in Review

Geode Capital Management increased its ADC Therapeutics (ADCT) stake by 20% in Q2 2026, buying an estimated $705K and bringing the position to 1,445,546 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #3246.

Geode Capital Management first reported a position in ADCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.51M in Q1 2026. 104 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Geode Capital Management held 1,445,546 shares of ADC Therapeutics worth $1.55M as of Q2 2026.
  • Geode Capital Management bought 241,790 ADC Therapeutics shares in Q2 2026, an estimated $705K.
  • ADC Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3246 holding.
  • Geode Capital Management first reported a position in ADC Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Geode Capital Management's ADC Therapeutics position peaked at $4.51M in Q1 2026.
  • 104 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.